{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT06889493","nct_id":"NCT06889493","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06889493. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants in this group will receive a single dose of SVV-001 on Day 1, in combination with Nivolumab and Ipilimumab therapy.\n\nTotal participation duration is up to 2 years.","label":"SVV-001 Single Dose Treatment Group","type":"EXPERIMENTAL"},{"description":"Participants in this group will receive multiple doses of SVV-001, beginning on Day 1, in combination with Nivolumab and Ipilimumab therapy.\n\nTotal participation duration is up to 2 years.","label":"SVV-001 Multi-Dose Treatment Group","type":"EXPERIMENTAL"},{"description":"Participants is this group will receive the recommended phase 2 dose and frequency of SVV-001 in combination with Nivolumab and Ipilimumab therapy.\n\nTotal participation duration is up to 2 years.","label":"SVV-001 RP2D Treatment Group","type":"EXPERIMENTAL"}],"collaborators":["Seneca Therapeutics"],"completion_date":{"date":"2030-06-01","type":"ESTIMATED"},"conditions":["Neuroendocrine Carcinoma","Neuroendocrine Tumors"],"enrollment":{"count":36,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Seneca Valley Virus-001 (SVV-001)","otherNames":[],"type":"BIOLOGICAL"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Ipilimumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-28","lead_sponsor":"Peter Hosein, MD","official_title":"A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2030-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose","timeFrame":"Up to 12 months"},{"measure":"Number of Participants Experiencing Dose Limiting Toxicities (DLTs): Part 1 Only","timeFrame":"Up to 12 months"},{"measure":"Number of Participants Experiencing Treatment-Related Serious Adverse Events (SAEs)","timeFrame":"Up to 12 months"},{"measure":"Number of Participants Experiencing Treatment-Related Adverse Events (AEs)","timeFrame":"Up to 12 months"}],"references":[],"start_date":{"date":"2025-05-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)","url":"https://clinicaltrials.gov/study/NCT06889493"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06889493"}